NCT00667641
- Conditions
- Adenocarcinoma, Adenocarcinoma, Papillary, Adnexal Diseases, +67 more
- Locations
-
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey, United States
Clinical trial condition
Adenocarcinoma, Papillary
Explore clinical trials studying Adenocarcinoma, Papillary. Study availability and eligibility vary by location and protocol.
137 public trials
26 recruiting studies
Adenocarcinoma, Papillary trial results
Active, Not Recruiting
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
NCT02650401
- Conditions
- Adenocarcinoma, Adenocarcinoma, Papillary, Brain Diseases, +59 more
- Locations
-
- University of California San Diego La Jolla, California, United States
- UCSF Benioff Children's Hospital San Francisco, California, United States
- Children's Hospital Colorado Aurora, Colorado, United States
- Egleston Children's Hospital at Emory University Atlanta Atlanta, Georgia, United States
Active, Not Recruiting
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
NCT03914300
- Conditions
- Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +20 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- Los Angeles General Medical Center Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- USC Norris Oncology/Hematology-Newport Beach Newport Beach, California, United States
Active, Not Recruiting
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02568267
- Conditions
- Adenocarcinoma, Adenocarcinoma, Papillary, Adnexal Diseases, +91 more
- Locations
-
- Dignity Health St Joseph's Hospital and Medical Center Phoenix, Arizona, United States
- Mayo Clinic Phoenix, Arizona, United States
- City of Hope Cancer Center Duarte, California, United States
- City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services Duarte, California, United States
Active, Not Recruiting
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
NCT04759911
- Conditions
- Adenocarcinoma, Adenocarcinoma, Papillary, Carcinoma, +25 more
- Locations
-
- Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
- University of Michigan Health Systems Ann Arbor, Michigan, United States
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
NCT01398085
- Conditions
- Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +13 more
- Locations
-
- Belfast Health and Social Care Trust Belfast, United Kingdom
- University Hospitals Birmingham NHS Foundation Trust Birmingham, United Kingdom
- University Hospitals Sussex NHS Foundation Trust Brighton, United Kingdom
- University Hospital Bristol NHS Foundation Trust Bristol, United Kingdom
Active, Not Recruiting
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
NCT01709292
- Conditions
- Adenocarcinoma, Adenocarcinoma, Papillary, Carcinoma, +11 more
- Locations
-
- University of Texas MD Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NCT03157128
- Conditions
- Adenocarcinoma, Adenocarcinoma, Papillary, Any Solid Tumor, +46 more
- Locations
-
- Mayo Clinic of Scottsdale Scottsdale, Arizona, United States
- City of Hope National Medical Center Duarte, California, United States
- UCLA Medical Center Los Angeles, California, United States
- Hoag Memorial Hospital Presbyterian Newport Beach, California, United States
Active, Not Recruiting
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
NCT02152995
- Conditions
- Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +23 more
- Locations
-
- Memorial Sloan Kettering Cancer Center New York, United States
Active, Not Recruiting
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
NCT04948437
- Conditions
- Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +14 more
- Locations
-
- Chih-Yuan Wang, M.D Taipei, Taiwan